Our Shareholders

  • Focused strategy for Africa with distribution capabilities in key African economies (21Countries).

  • Ability to grow in a highly volatile emerging market.

  • Innovative and goal driven Healthcare company (Pharma, Disposables, Devices and Ortho):

  • Over 9,000 products

  • 25 years of experience

  • 800 employees

  • 35 regulatory pharmacists

  • 9 health care production facilities

  • US$160 million annual turnover

  • Accessing high value dossiers (Proprietary IP) from across the globe building and sustaining long term partnerships

  • Click here to visit their website

  • Established: 1940

  • Type of organisation: Development Finance Institution (DFI)

  • Ownership: 100% owned by South African Government

  • Total assets: USD 9.6 billion (31 March 2017 – group)

  • Total liabilities: USD 3.1 billion (31 March 2017 – group)

  • Funding status: Fund operations and growth from investments, pay dividends & income tax

  • Credit rating: Baa3 (Moody’s)

  • Main business area: Providing funding for big business, entrepreneurs and projects contributing to industrialization

  • Geographic activities: South Africa and the rest of Africa

  • Stage of investment: Project identification and development, feasibility, commercialization, expansion, modernization

  • No. of employees: 839 (March 2017)

  • Operational footprint: Head Office in Johannesburg & 20 Regional and Satellite offices

  • Click here to visit their website

Afrigen Biologics Board

MembersChairperson: Mr Mehmet Levent Selamoglu (Turkey).

Non-Executive Directors: Dr Vikramkumar Naik, Dr Tadesse Teferi Mekonen (Ethiopian),    Dr Ntuthuko Melusi Bhengu, Dr Vathiswa Belinda Papu-Zamxaka,
Mr Shawn Renders, Mr Andrè Meyer.        

Executive Directors: Prof Aletta Petronella Susarah Terblanche (Managing Director,              Ex-Officio Member of the Board); and Dr Caryn Janine Fenner (Alternate Director).
Company Secretary: Felicity Ranthako